Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.

Name: Kaimen Rigor review — A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.
Item: A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.
Rating: 94
Author: Alpha1

Diacon AH, Barry CE 3rd, Carlton A, Chen RY, Davies M, de Jager V, Fletcher K, Koh GCKW, Kontsevaya I, Heyckendorf J, Lange C, Reimann M, Penman SL, Scott R, Maher-Edwards G, Tiberi S, Vlasakakis G, Upton CM, Aguirre DB

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3★ (Adequate), 0 critical, 3 high issues for “A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.

Read full text (PMC)

DOI

10.1038/s41591-024-02829-7

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/bbbb94fc-348a-4292-ada4-b5135587eddd" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/bbbb94fc-348a-4292-ada4-b5135587eddd/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 3 high issues for “A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

780ba7625bb98caf942cbb96ce4ff16f6d10347c6d2258d70491f486ff235ca3

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.

Paper source

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy endpoint is early bactericidal activity (EBA), measured as the rate of change in log10 CFU/ml sputum and time to sputum culture positivity (TTP). These are microbiological surrogate markers for clinical outcome (cure, relapse, mortality). The paper does not provide evidence linking EBA to long-term clinical outcomes, nor does it demonstrate target engagement at the tested doses beyond PK/PD modeling. The claim of 'bactericidal activity' is based on these surrogate endpoints.
“Assessing the EBA (the measure of efficacy used in this study) of anti-TB drugs by determining the viable sputum load of M. tuberculosis over the first 14 days of treatment is an established method for the early clinical evaluation of new agents”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect sizes are numerical reductions in log10 CFU/ml sputum, but the magnitude is not anchored to a clinically meaningful threshold. The paper does not state a minimal clinically important difference for EBA, and the reductions are described as 'numerical' without statistical significance testing. The effect size is not presented as a fraction of normal or compared to a reference value.
“We observed numerical reductions in daily sputum-derived colony-forming units from baseline in participants receiving 5, 15 and 30 mg once daily but not those receiving 1 mg ganfeborole.”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 105AvailabilityBroken references and links 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted phase 2a dose-ranging trial with clear scientific premise, adequate ethics, and transparent reporting. The main weaknesses are the absence of a formal power analysis, partial blinding, and lack of explicit outlier handling, which are typical for exploratory phase 2a studies but should be acknowledged.

Both reviewers classified the study as interventional; no divergence. The statistics component recomputed 0 tests (coverage limited to tests with test statistic+df or effect+CI), so no statistical claims are independently verified. The citation check found 1 reference not found in registry (potential fabrication signal).

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Study-design details incomplete (controls, blinding, power)Assessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior in vitro, animal, and phase 1 studies of ganfeborole, and explains the need for new TB treatments. The rationale linking the drug's mechanism to the study objectives is clear. Limitations of prior work are implicitly addressed through the study design and discussion.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 3]

“Ganfeborole has displayed promising activity in vitro against laboratory strains of M. tuberculosis ... In mice, ganfeborole showed 100% bioavailability, excellent exposure and low clearance, and antitubercular activity.”

“In this article, a phase 2a randomized study, the aim was to assess the EBA, safety, and PK of ganfeborole monotherapy at a range of dosages in male participants with a new episode of untreated, rifampicin-susceptible pulmonary TB.”

Introduction ¶4Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 3]

paraphrase[Introduction, paragraph 4]

“A population PK analysis together with a translational PK/pharmacodynamics (PK/PD) model were then used to inform the clinical doses in this subsequent phase 2a study.”

“New tuberculosis treatments are needed to address drug resistance, lengthy treatment duration and adverse reactions of available agents.”

Introduction ¶1Find in source

Randomization method (permuted blocks) and unit (participant) are reported. Blinding is partial: open-label for participants and investigators, but laboratory staff blinded. A formal power analysis is absent, though simulations are described. Inclusion/exclusion criteria are detailed. Outlier handling is not explicitly described. The SOC group serves as a control. Independent replication is not applicable for a single trial.

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsINADEQUATE

outlier handlingNOT REPORTED

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

The study design is appropriate for a phase 2a dose-ranging trial, but lacks a formal power analysis and has limited blinding.

Evidence

“Within each cohort, participants were randomized 3:1 to receive ganfeborole or SOC for drug-susceptible TB using permutated blocks.”

MethodsFind in source

“The study was open label, so neither the participants nor the primary investigators were blinded. However, all laboratory staff involved in analyzing and reporting the log 10 CFU counts and TTP endpoints results were blinded to treatment allocation.”

MethodsFind in source

“As no formal statistical hypothesis was tested, no formal sample size calculation was performed.”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The study design is appropriate for a phase 2a dose-ranging trial, with randomization, blinding of laboratory staff, and a clear description of the analysis populations.

Evidence

“Within each cohort, participants were randomized 3:1 to receive ganfeborole or SOC for drug-susceptible TB using permutated blocks.”

MethodsFind in source

“However, all laboratory staff involved in analyzing and reporting the log 10 CFU counts and TTP endpoints results were blinded to treatment allocation.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

“Assuming a true underlying change from baseline of −0.06 and a sample size of 15 participants per group, there was approximately 90% probability of the observed mean change being a negative value.”

Sex (all male) is reported and justified by teratogenicity data. Age, weight, BMI, and health status (HIV status) are reported. Demographics (race, smoking) are reported. Species/strain and housing are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedADEQUATE

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for a human trial, including sex, age, weight, and demographics.

Evidence

“All participants were male due to preclinical teratogenicity data from animal models that became available after the phase 1 study.”

MethodsFind in source

“All participants were Black, and most smoked <20 cigarettes per day.”

Table 1Find in source

PASSReviewer 2· 90% conf

Biological variables are well reported for a human clinical trial, including sex, age, weight, and demographics.

Evidence

“All participants were male due to preclinical teratogenicity data from animal models that became available after the phase 1 study.”

MethodsFind in source

“Age (years), mean (s.d.) | 37.0 (10.20) | 37.8 (8.38) | 38.1 (10.33) | 39.8 (12.33) | 38.5 (9.82)”

Table 1Find in source

“All participants were Black, and most smoked <20 cigarettes per day.”

ResultsFind in source

The study was approved by a named ethics committee (Pharma-Ethics, South Africa) and regulatory authority. Written informed consent was obtained. Compliance with the Declaration of Helsinki and GCP is stated.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are adequately reported.

Evidence

“Ethical approval was granted by Pharma-Ethics, South Africa.”

MethodsFind in source

“All participants provided written informed consent before the performance of any study-specific procedures.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are clearly documented.

Evidence

“Ethical approval was granted by Pharma-Ethics, South Africa.”

MethodsFind in source

“All participants provided written informed consent before the performance of any study-specific procedures.”

MethodsFind in source

“The study was conducted in accordance with ethical principles that have their origins in the Declaration of Helsinki and the principles of good clinical practice.”

MethodsFind in source

The investigational product (ganfeborole) is named with doses and regimen. SOC (Rifafour e-275) is named. Software tools (MIM Maestro, CIBERSORT) are identified with versions. Antibodies, cell lines, and mycoplasma testing are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product and key software are identified adequately.

Evidence

paraphrase[Methods, Treatment and assessments]

“SOC (Rifafour e-275 or generic alternative) was weight adjusted per the South African National Tuberculosis Management Guidelines 2014.”

“For the manual analysis, which was carried out by an appropriately trained reader, regions of interest spanning the entire left or right lung were defined in MIM Maestro (6.7.12).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product and key software are identified, though some details are incomplete.

Evidence

paraphrase[Methods, Treatment and assessments]

“Participants orally received either SOC or ganfeborole 1–30 mg QD. SOC (Rifafour e-275 or generic alternative) was weight adjusted per the South African National Tuberculosis Management Guidelines 2014.”

“For the manual analysis, which was carried out by an appropriately trained reader, regions of interest spanning the entire left or right lung were defined in MIM Maestro (6.7.12).”

Statistical analysisFind in source

“This formed the basis for the application of the CIBERSORT algorithm ( https://cibersortx.stanford.edu/ ).”

Statistical analysisFind in source

Statistical tests are named (mixed model repeated measures, Bayesian regression). Assumptions are handled by design. Exact p-values are not reported; the study uses estimation with CIs. Effect sizes with CIs are reported. Software is identified. Data presentation includes per-group n and CIs. Mathematical plausibility checks were not possible for most data due to continuous outcomes and model-based estimates.

Sub-criteria

tests namedADEQUATE

exact p valuesN/A

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical methods are appropriate and adequately reported, with no demonstrable errors.

Evidence

“The primary and secondary efficacy analyses were performed using a mixed model repeated measures analysis.”

Statistical analysisFind in source

“Data are mean estimate (95% CI).”

Figure 2Find in source

PASSReviewer 2· 80% conf

Statistical methods are appropriate and well described, with effect estimates and confidence intervals reported.

Evidence

“The primary and secondary efficacy analyses were performed using a mixed model repeated measures analysis.”

Statistical analysisFind in source

“Data are mean estimate (95% CI).”

Figure 2Find in source

“Safety data were summarized descriptively according to the Medical Dictionary for Regulatory Activities version 24.1 and GSK’s Integrated Data Standards Library standards.”

Statistical analysisFind in source

The data availability statement describes a managed access process via GSK's data sharing portals, which is appropriate for patient-level data. No raw data repository deposit or accession numbers are applicable for patient-level data. Code sharing is not applicable as no bespoke code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a concrete access route.

Evidence

“External researchers can request access to anonymized patient-level clinical trial data and supporting clinical trial documents through either of two multi-sponsor data sharing portals.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is well described with a concrete access route via GSK's data sharing portal.

Evidence

“External researchers can request access to anonymized patient-level clinical trial data and supporting clinical trial documents through either of two multi-sponsor data sharing portals.”

Data availabilityFind in source

The trial is registered (NCT03557281). A reporting summary is mentioned. All outcomes are reported. Limitations are discussed. Conclusions are proportional. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, limitations, and funding disclosures.

Evidence

“ClinicalTrials.gov identifier: NCT03557281”

AbstractFind in source

“This study has several limitations. The study design did not include a negative control as it is unethical to have a no treatment or placebo group of participants with active TB.”

DiscussionFind in source

PASSReviewer 2· 85% conf

The manuscript is transparent, with trial registration, a reporting summary, and discussion of limitations.

Evidence

“ClinicalTrials.gov identifier: NCT03557281”

AbstractFind in source

“Further information on research design is available in the linked to this article.”

AbstractFind in source

“This study has several limitations. The study design did not include a negative control as it is unethical to have a no treatment or placebo group of participants with active TB.”

Discussion ¶4Find in source

Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 34 references by DOI: 25 verified — 1 DOI unresolved, 8 no DOI (shown, not verified).

4 data/code links checked; 4 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is generally robust, but readers should weigh the lack of formal power analysis and partial blinding when interpreting effect sizes. The unresolved reference and minor internal inconsistencies (e.g., 75 vs 76 participants) warrant attention; an erratum or clarification may be appropriate.

1.
HIGHreporting
In the Methods, Statistical analysis section, add a statement on how outliers were handled, or explicitly state that no outliers were excluded.
Outlier handling is a standard reporting requirement and its absence is a gap that readers may question.
2.
HIGHreporting
In the Methods, clarify the role of the bilinear Bayesian regression model (primary vs sensitivity analysis) and specify the statistical software (e.g., SAS, R) with version numbers.
Ambiguity in the analysis plan and missing software details reduce reproducibility.
3.
HIGHreporting
Verify and correct the reference 'The early bactericidal activity of drugs in patients with pulmonary tuberculosis' (DOI 10.1164/arrd.1980.121.6.939) which was not found in Crossref/OpenAlex; confirm it exists or replace it.
An unresolved reference may indicate a fabrication or citation error, which is a serious integrity concern.
4.
MEDIUMreporting
In the Results, reconcile the discrepancy between the abstract's '75 males were treated' and the results' '76 enrolled and randomized'; clarify whether one participant did not receive treatment.
Internal inconsistency in participant numbers could confuse readers and undermine trust.
5.
MEDIUMreporting
In the Methods, specify the manufacturer/source of ganfeborole and the SOC (Rifafour e-275) to fully identify the investigational products.
Complete identification of key resources is essential for reproducibility.
6.
MEDIUMreporting
In the Methods, provide version numbers for all software used (e.g., custom segmentation software) to enhance reproducibility.
Missing software versions hinder replication of the analysis.
7.
MEDIUMreporting
In the Results, consider reporting exact p-values for key comparisons, even though the study is primarily estimation-based, to facilitate meta-analyses.
Exact p-values are useful for future meta-analyses and are expected by some readers.
8.
MEDIUMreporting
In the Discussion, explicitly address the potential impact of the open-label design on the results, even though laboratory staff were blinded.
Acknowledging the limitation of open-label design strengthens the interpretation.
9.
MEDIUMdata code
In the Data Availability section, provide a direct link to the data sharing portal or a specific accession number for the dataset.
A concrete link or accession number makes the data access route more actionable.
10.
MEDIUMreporting
In the Methods, state whether any data were imputed for missing sputum samples or other missing data.
Handling of missing data is a key methodological detail that is currently absent.
11.
MEDIUMreporting
In the Results, for the PET/CT exploratory analysis, report the number of participants with each lesion type to clarify the subgroup analyses.
Providing subgroup sample sizes improves transparency of exploratory analyses.
12.
MEDIUMreporting
In the Discussion, clarify that the PET/CT and transcriptional analyses are exploratory and hypothesis-generating, not confirmatory.
Explicitly labeling exploratory analyses prevents over-interpretation.
13.
LOWcopyedit
Fix typo 'langauge' to 'language' in Extended Data Table 1.
Correcting typos improves professionalism.
14.
LOWcopyedit
Use superscript for 18F in '18F-fluorodeoxyglucose' in the Abstract.
Proper formatting of isotopes is standard scientific notation.
15.
LOWcopyedit
Verify the enrollment number '76 (45%)' against the CONSORT diagram in the Results.
Ensuring consistency between text and CONSORT diagram is important for reporting accuracy.

Full text (53,442 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.

Read full text (PMC)

DOI

10.1038/s41591-024-02829-7

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/bbbb94fc-348a-4292-ada4-b5135587eddd" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/bbbb94fc-348a-4292-ada4-b5135587eddd/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 3 high issues for “A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

780ba7625bb98caf942cbb96ce4ff16f6d10347c6d2258d70491f486ff235ca3

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy endpoint is early bactericidal activity (EBA), measured as the rate of change in log10 CFU/ml sputum and time to sputum culture positivity (TTP). These are microbiological surrogate markers for clinical outcome (cure, relapse, mortality). The paper does not provide evidence linking EBA to long-term clinical outcomes, nor does it demonstrate target engagement at the tested doses beyond PK/PD modeling. The claim of 'bactericidal activity' is based on these surrogate endpoints.
“Assessing the EBA (the measure of efficacy used in this study) of anti-TB drugs by determining the viable sputum load of M. tuberculosis over the first 14 days of treatment is an established method for the early clinical evaluation of new agents”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect sizes are numerical reductions in log10 CFU/ml sputum, but the magnitude is not anchored to a clinically meaningful threshold. The paper does not state a minimal clinically important difference for EBA, and the reductions are described as 'numerical' without statistical significance testing. The effect size is not presented as a fraction of normal or compared to a reference value.
“We observed numerical reductions in daily sputum-derived colony-forming units from baseline in participants receiving 5, 15 and 30 mg once daily but not those receiving 1 mg ganfeborole.”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 105AvailabilityBroken references and links 06Copyedit5 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Study-design details incomplete (controls, blinding, power)Assessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 3]

Introduction ¶4Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 3]

paraphrase[Introduction, paragraph 4]

“A population PK analysis together with a translational PK/pharmacodynamics (PK/PD) model were then used to inform the clinical doses in this subsequent phase 2a study.”

“New tuberculosis treatments are needed to address drug resistance, lengthy treatment duration and adverse reactions of available agents.”

Introduction ¶1Find in source

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsINADEQUATE

outlier handlingNOT REPORTED

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

The study design is appropriate for a phase 2a dose-ranging trial, but lacks a formal power analysis and has limited blinding.

Evidence

“Within each cohort, participants were randomized 3:1 to receive ganfeborole or SOC for drug-susceptible TB using permutated blocks.”

MethodsFind in source

“As no formal statistical hypothesis was tested, no formal sample size calculation was performed.”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The study design is appropriate for a phase 2a dose-ranging trial, with randomization, blinding of laboratory staff, and a clear description of the analysis populations.

Evidence

“Within each cohort, participants were randomized 3:1 to receive ganfeborole or SOC for drug-susceptible TB using permutated blocks.”

MethodsFind in source

“However, all laboratory staff involved in analyzing and reporting the log 10 CFU counts and TTP endpoints results were blinded to treatment allocation.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedADEQUATE

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for a human trial, including sex, age, weight, and demographics.

Evidence

“All participants were male due to preclinical teratogenicity data from animal models that became available after the phase 1 study.”

MethodsFind in source

“All participants were Black, and most smoked <20 cigarettes per day.”

Table 1Find in source

PASSReviewer 2· 90% conf

Biological variables are well reported for a human clinical trial, including sex, age, weight, and demographics.

Evidence

“All participants were male due to preclinical teratogenicity data from animal models that became available after the phase 1 study.”

MethodsFind in source

“Age (years), mean (s.d.) | 37.0 (10.20) | 37.8 (8.38) | 38.1 (10.33) | 39.8 (12.33) | 38.5 (9.82)”

Table 1Find in source

“All participants were Black, and most smoked <20 cigarettes per day.”

ResultsFind in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are adequately reported.

Evidence

“Ethical approval was granted by Pharma-Ethics, South Africa.”

MethodsFind in source

“All participants provided written informed consent before the performance of any study-specific procedures.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are clearly documented.

Evidence

“Ethical approval was granted by Pharma-Ethics, South Africa.”

MethodsFind in source

“All participants provided written informed consent before the performance of any study-specific procedures.”

MethodsFind in source

“The study was conducted in accordance with ethical principles that have their origins in the Declaration of Helsinki and the principles of good clinical practice.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product and key software are identified adequately.

Evidence

paraphrase[Methods, Treatment and assessments]

“SOC (Rifafour e-275 or generic alternative) was weight adjusted per the South African National Tuberculosis Management Guidelines 2014.”

“For the manual analysis, which was carried out by an appropriately trained reader, regions of interest spanning the entire left or right lung were defined in MIM Maestro (6.7.12).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product and key software are identified, though some details are incomplete.

Evidence

paraphrase[Methods, Treatment and assessments]

“For the manual analysis, which was carried out by an appropriately trained reader, regions of interest spanning the entire left or right lung were defined in MIM Maestro (6.7.12).”

Statistical analysisFind in source

“This formed the basis for the application of the CIBERSORT algorithm ( https://cibersortx.stanford.edu/ ).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesN/A

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical methods are appropriate and adequately reported, with no demonstrable errors.

Evidence

“The primary and secondary efficacy analyses were performed using a mixed model repeated measures analysis.”

Statistical analysisFind in source

“Data are mean estimate (95% CI).”

Figure 2Find in source

PASSReviewer 2· 80% conf

Statistical methods are appropriate and well described, with effect estimates and confidence intervals reported.

Evidence

“The primary and secondary efficacy analyses were performed using a mixed model repeated measures analysis.”

Statistical analysisFind in source

“Data are mean estimate (95% CI).”

Figure 2Find in source

“Safety data were summarized descriptively according to the Medical Dictionary for Regulatory Activities version 24.1 and GSK’s Integrated Data Standards Library standards.”

Statistical analysisFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a concrete access route.

Evidence

“External researchers can request access to anonymized patient-level clinical trial data and supporting clinical trial documents through either of two multi-sponsor data sharing portals.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is well described with a concrete access route via GSK's data sharing portal.

Evidence

“External researchers can request access to anonymized patient-level clinical trial data and supporting clinical trial documents through either of two multi-sponsor data sharing portals.”

Data availabilityFind in source

The trial is registered (NCT03557281). A reporting summary is mentioned. All outcomes are reported. Limitations are discussed. Conclusions are proportional. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, limitations, and funding disclosures.

Evidence

“ClinicalTrials.gov identifier: NCT03557281”

AbstractFind in source

“This study has several limitations. The study design did not include a negative control as it is unethical to have a no treatment or placebo group of participants with active TB.”

DiscussionFind in source

PASSReviewer 2· 85% conf

The manuscript is transparent, with trial registration, a reporting summary, and discussion of limitations.

Evidence

“ClinicalTrials.gov identifier: NCT03557281”

AbstractFind in source

“Further information on research design is available in the linked to this article.”

AbstractFind in source

“This study has several limitations. The study design did not include a negative control as it is unethical to have a no treatment or placebo group of participants with active TB.”

Discussion ¶4Find in source

Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 34 references by DOI: 25 verified — 1 DOI unresolved, 8 no DOI (shown, not verified).

4 data/code links checked; 4 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHreporting
In the Methods, Statistical analysis section, add a statement on how outliers were handled, or explicitly state that no outliers were excluded.
Outlier handling is a standard reporting requirement and its absence is a gap that readers may question.
2.
HIGHreporting
In the Methods, clarify the role of the bilinear Bayesian regression model (primary vs sensitivity analysis) and specify the statistical software (e.g., SAS, R) with version numbers.
Ambiguity in the analysis plan and missing software details reduce reproducibility.
3.
HIGHreporting
Verify and correct the reference 'The early bactericidal activity of drugs in patients with pulmonary tuberculosis' (DOI 10.1164/arrd.1980.121.6.939) which was not found in Crossref/OpenAlex; confirm it exists or replace it.
An unresolved reference may indicate a fabrication or citation error, which is a serious integrity concern.
4.
MEDIUMreporting
In the Results, reconcile the discrepancy between the abstract's '75 males were treated' and the results' '76 enrolled and randomized'; clarify whether one participant did not receive treatment.
Internal inconsistency in participant numbers could confuse readers and undermine trust.
5.
MEDIUMreporting
In the Methods, specify the manufacturer/source of ganfeborole and the SOC (Rifafour e-275) to fully identify the investigational products.
Complete identification of key resources is essential for reproducibility.
6.
MEDIUMreporting
In the Methods, provide version numbers for all software used (e.g., custom segmentation software) to enhance reproducibility.
Missing software versions hinder replication of the analysis.
7.
MEDIUMreporting
In the Results, consider reporting exact p-values for key comparisons, even though the study is primarily estimation-based, to facilitate meta-analyses.
Exact p-values are useful for future meta-analyses and are expected by some readers.
8.
MEDIUMreporting
In the Discussion, explicitly address the potential impact of the open-label design on the results, even though laboratory staff were blinded.
Acknowledging the limitation of open-label design strengthens the interpretation.
9.
MEDIUMdata code
In the Data Availability section, provide a direct link to the data sharing portal or a specific accession number for the dataset.
A concrete link or accession number makes the data access route more actionable.
10.
MEDIUMreporting
In the Methods, state whether any data were imputed for missing sputum samples or other missing data.
Handling of missing data is a key methodological detail that is currently absent.
11.
MEDIUMreporting
In the Results, for the PET/CT exploratory analysis, report the number of participants with each lesion type to clarify the subgroup analyses.
Providing subgroup sample sizes improves transparency of exploratory analyses.
12.
MEDIUMreporting
In the Discussion, clarify that the PET/CT and transcriptional analyses are exploratory and hypothesis-generating, not confirmatory.
Explicitly labeling exploratory analyses prevents over-interpretation.
13.
LOWcopyedit
Fix typo 'langauge' to 'language' in Extended Data Table 1.
Correcting typos improves professionalism.
14.
LOWcopyedit
Use superscript for 18F in '18F-fluorodeoxyglucose' in the Abstract.
Proper formatting of isotopes is standard scientific notation.
15.
LOWcopyedit
Verify the enrollment number '76 (45%)' against the CONSORT diagram in the Results.
Ensuring consistency between text and CONSORT diagram is important for reporting accuracy.

Full text (53,442 chars)Analyzed: Aug 16, 2026